Kamal Thammi Reddy

Employment

• Biological E (India) Senior Manager - Clinical Development
  2020 - Present

Education

• Sri Krishnadevaraya University M.Sc
  2000 - 2002

Projects & Funding

Projects & funding information is unavailable.

Publications (4)

• Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14®) Administered at 6–10–14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial
  Vaccines 2026 DOI: 10.3390/vaccines14060464
  +Save
• Immunogenicity and Safety of Biological E’s Monovalent rDNA Hepatitis B Vaccine (BEVAC®) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial
  Viruses 2026 DOI: 10.3390/v18040472
  +Save
• Immunogenicity and safety of Biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial
  The Lancet Regional Health - Southeast Asia 2026 DOI: 10.1016/j.lansea.2026.100746
  +Save
• Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6–8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study
  Vaccine 2024 DOI: 10.1016/j.vaccine.2024.03.056
  +Save